SCHEMBL6087786

SCHEMBL6087786

NC1CCC(c2cc3ccccc3[nH]2)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMYD3 Q9H7B4 1/20 0.42
AOC3 Q16853 2/20 0.42
VCP P55072 1/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
LOXL2 Q9Y4K0 1/20 0.39
SLC6A3 Q01959 3/20 0.38
SLC6A4 P31645 2/20 0.38
CA2 P00918 2/20 0.37
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
MAPT P10636 2/20 0.36
MEN1 O00255 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
CYP2C19 P33261 1/20 0.36
CASP3 P42574 1/20 0.36
KMT2A Q03164 1/20 0.36
SENP8 Q96LD8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL73543 0.84 AOC3 (0.47) AOC3NPC1RAB9ALOXL2SLC6A3
SCHEMBL3640169 0.78 AOC3 (0.44) AOC3NPC1RAB9ALOXL2KDM4E
SCHEMBL10441226 0.76 AOC3 (0.42) AOC3NPC1RAB9ALOXL2KDM4E
SCHEMBL7968720 0.75 HTR2A (0.47) AOC3NPC1RAB9ALOXL2SLC6A3
SCHEMBL12534038 0.75 AOC3 (0.41) AOC3NPC1RAB9ALOXL2SLC6A3
SCHEMBL29688552 0.75 MAOB (0.49) AOC3SLC6A3SLC6A4MAPT
SCHEMBL1237690 0.75 MAOB (0.49) AOC3SLC6A3SLC6A4MAPT
SCHEMBL5584506 0.73 AOC3 (0.40) AOC3VCPNPC1RAB9ALOXL2
SCHEMBL7973510 0.72 SLC6A3 (0.43) VCPSLC6A3SLC6A4CHRNA7
SCHEMBL7203954 0.71 HRH4 (0.53) VCPCHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7049314-B2 Sexual disorders; antidepressants; attention deficit hyperactivity, obsessive-compulsive, and/or post-traumatic stress disorder; drug abuse and addiction BRISTOL-MYERS SQUIBB COMPANY (US) 2006-05-23 US disclosed
US-20040077705-A1 Cyclopentyl indole derivatives BRISTOL-MYERS SQUIBB COMPANY 2004-04-22 US disclosed
WO-2004026236-A2 CYCLOPENTYL INDOLE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2004-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077705-A1 Cyclopentyl indole derivatives HTR5A, TPH1, TPH2 SMYD3 4193/4885AOC3 1641/4885VCP 1635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.